We have established an experimental murine model to gain insight into the pathogenicity and clinical features of type IV group B streptococcus (GBS) infections. Adult CD-1 mice were challenged intravenously with 107 type IV GBS cells, inducing systemic invasion. Most of the animals were able to clear the infection from the blood, brain, and lungs within 2 weeks and from the spleen and liver within 1 month. However, the animals were unable to clear the microorganism from the joints and kidneys during the 60-day observation period. About 80% of the mice challenged intravenously with type IV GBS manifested early septic arthritis, which evolved from an acute exudative synovitis to permanent lesions characterized by irreversible joint damage and ankylosis. Induction of persistent septic arthritis was dependent on the number and viability of microorganisms inoculated and was unrelated to the strain of type IV GBS and the growth phase of the inoculum. Type-specific antibodies of both immunoglobulin M and G classes could be detected by agglutination and enzyme-linked immunosorbent assay from days 7 and 14, respectively; immunoglobulin G antibodies persisted for more than 40 days. Complexes of antibodies and group-and type-specific antigens were detected in mouse sera 24 h after infection and persisted up to day 22. These results were obtained an experimental model of type IV GBS chronic infection with early development of septic arthritis, which could be useful in future studies of pathogenicity and immune mechanisms involved in the host resistance to this microorganism.
Group B streptococci (GBS) are important human pathogens which cause serious neonatal diseases (1, 16) . All GBS serotypes cause early-onset infections, and type III is associated with the majority of late-onset infections, (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . Recently, two new GBS serotypes, type IV and provisional type V, have been reported (17-19, 24, 26) . Type IV GBS is characterized by a serologically specific type polysaccharide localized on the bacterial surface (23, 35) . However, little is known about type IV GBS pathogenicity and the immune mechanisms of resistance to infection (23) (24) (25) , due, in part, to lack of a suitable experimental model. Relevant results for a better understanding of human diseases have been obtained by studying type I, II, and III GBS infections in adult mice (6, 9, 12, 14, 27, 34) as well as infant and adult rats (11, 30) .
The purpose of this investigation was to establish an experimental murine model of infection to evaluate pathogenicity and clinical features of type IV GBS infection. In particular, we demonstrate that systemic challenge of mice with type IV GBS results in chronic infection with a high incidence of early septic arthritis and that this phenomenon is not strain specific.
MATERIALS AND METHODS
Animals. Outbred CD-1 mice of both sexes, 8 to Preparation of antisera. Group-and type-specific antisera were prepared in New Zealand White rabbits by the method of Lancefield (21) . Group-specific antisera were obtained by using the group B reference strain; type IV specific antisera were prepared by i.v. inoculation of type IV GBS 1/82. Sera were collected after 6 weeks and tested for group-and type-specific antibodies by agar immunodiffusion. The sera were stored at -70°C.
Enzyme-linked immunosorbent assay. Specific immunoglobulin G (IgG) or IgM antibodies against GBS type IV polysaccharide were measured by enzyme-linked immunosorbent assay. GBS type IV polysaccharide antigen was extracted by the method of Wilkinson and Jones (36) and purified by wheatgerm agglutinin affinity chromatography (15) . The antigen was checked for specificity in immunodiffusion against type IV and group B immune rabbit sera.
Flat-bottom plates (Microelisa; Dynatech, Alessandria, Italy) were coated overnight at room temperature with 1 ,ug of the antigen, suspended in 0.1 M carbonate buffer, pH 9.6. Plates were then washed with phosphate-buffered salineTween 20 (0.05%, vol/vol), and mouse serum samples diluted 1:100 in phosphate-buffered saline-Tween 20 plus 0.01% gelatin were added. After 2 h of incubation at room temperature and three washings, 200 ,ul of goat anti-mouse IgG or anti-mouse IgM alkaline phosphatase-conjugated antiserum (Sigma Chemical Co., St. Louis, Mo.) diluted 1:1,000 in phosphate-buffered saline-Tween-gelatin was added and plates were incubated for 2 h at room temperature. After washing, 200 RId of a 1-mg/ml concentration of p-nitrophenylphosphate (Sigma) diluted in diethanolamine buffer was added. After 1 h, the optical density was read at 405 nm with a Titertek Multiscan (Skatron, Oslo, Norway). Results were expressed as change in optical density at 405 nm, calculated for each serum sample by subtracting the absorbance of the serum in the absence of the coating antigen.
A well was considered positive for the presence of specific antibodies when its absorbance was at least twice the absorbance of the wells coated only with the antigen. Specific antibody titers were determined in pooled sera from three animals for each determination point.
Agglutination reaction. Slide agglutination tests were performed by mixing 10 ,ul of type IV GBS 1/82 cells from a thick suspension in phosphate-buffered saline with undiluted or a 1:5, 1:10, or 1:100 dilution of mouse sera collected at different times after bacterial challenge.
Antigenemia detection. The presence of free circulating type-and group-specific antigens was examined by immunodiffusion of sera of i.v. infected mice against anti-type IV and -group B rabbit immune sera. A commercial latex agglutination rapid test (Oxoid Ltd.) was also used to detect antibodylinked group B antigen. Latex agglutination and immunodiffusion tests were repeated with sera of infected mice pretreated with pronase (0.1 mg/ml) for 24 h and then boiled for 15 min and centrifuged at 3,000 rpm for 15 min. Irrelevant anti-type IV serum was used as a specificity control.
RESULTS
Effect of inoculum size on mouse mortality after challenge with different strains of type IV GBS. The capacity of the different strains of type IV GBS in the stationary phase of growth to produce lethal infection was examined by i.v. inoculation of mice with different numbers of microorganisms. The results (Table 1) show similar mortality rates for mice inoculated with the three strains of type IV GBS with low pathogenicity; inoculation of 106 GBS did not cause death. LD50s of the three GBS strains grown to the log or stationary phases were also evaluated. In Table 2 similar LD5Os were recorded regardless of the phase of growth of the inoculated microorganism. The sialic acid content of the GBS strains, evaluated at various times during 24-h culture, ranged from 0.74 to 0.89% (dry weight) of whole microbial cells. Experiments on in vivo growth of the three strains of type IV GBS were carried out by quantitative monitoring of bacteremia and GBS growth in the kidneys 3 and 10 days after systemic infection. The persistence of bacteremia and bacterial burden in the kidneys was dependent on inoculum size but not on the strain of GBS (Table 3) . In other experiments, the growth kinetics of GBS 1/82 in various organs of mice injected i.v. with 107 microorganisms was examined. All organs, except the brain, were colonized 2 h after challenge (Fig. 1 ), but after 24 h GBS 1/82 was present also in the brain and with increased numbers in all other organs examined. Subsequently, the number of microorganisms in the spleen, liver, lungs, and brain decreased while progressively increasing in the kidneys. In this organ, an apparent plateau of about 1010 GBS was maintained from 15 to 20 days, and an elevated number of CFUs was still present 1 month after challenge (Fig. 1) . Some 50 days after infection, GBS 1/82 could still be isolated from the kidneys of about 11% of the animals (data not shown). Clinical observations. Mice injected i.v. with 107 GBS of the three strains were examined for signs and symptoms of disease throughout the 60-day observation period. All animals manifested one or more of the following clinical signs: neurological disorders (circling, incoordinate movements, holding the head to one side) and panophthalmitis. In particular, the majority of mice manifested articular swelling. The kinetics of appearance and the incidence of this inflammation are reported in Table 4 . Clinical onset of articular lesions occurred with all GBS strains about 2 days after infection. The most involved joints were the ankle, wrist, and coxaphemoral joint, and, less frequently, tarsophalangeal, carpophalangeal, and interphalangeal joints. On day 8 after infection 77% of the animals showed persistent articular inflammation. Complete remission occurred only in 20% of the affected mice within 20 days. On day 60, animals with permanent lesions showed irreversible joint damage with marked ankylosis. Type IV GBS was constantly isolated from articular lesions during the whole course of infection with the three GBS strains.
Induction of joint arthritis was dependent on both the number of GBS inoculated and the viability of the microorganisms, because no clinical signs of inflammation were evident in mice infected i.v. with 106 microorganisms or inoculated with inactivated cells or whole-cell sonic extracts. The development of arthritis was similar with all strains of GBS ( linked immunosorbent assay methods (Fig. 3) . Agglutinating antibodies appeared on day 7 and persisted for at least 30 days. No prozone phenomenon was evident during week 1 of infection, as shown by the use of 1:5-to 1:100-diluted sera in the agglutination test. Enzyme-linked immunosorbent assaydetermined IgM antibodies to type-specific polysaccharide were demonstrable between days 5 and 7 and persisted until week 3 of infection, while IgG antibodies were detected on day 13, increased until day 30, and persisted for >40 days (data not shown).
Serum samples from infected mice were also investigated for the presence of group-and type-specific GBS antigens. While no evidence for these antigens was found by immunodiffusion or latex agglutination in untreated sera, both antigens were detected in sera pretreated with pronase. Group-specific antigen was revealed by latex agglutination as early as 24 h after infection and was still detectable on day 22 . Type IV antigen gave a light but discrete band in immunodiffusion against specific rabbit antiserum from days 5 to 16 after infection. Normal mice sera were negative for both group-and type-specific antigens.
DISCUSSION
Type IV GBS is a new serotype recently identified on the basis of the polysaccharide antigen. The original type IV GBS reference strain (GBS 1/82) was isolated from a case of neonatal sepsis (28) . Strains carrying type IV polysaccharide have since been isolated from carriers and from pathologic specimens (17, 18, 24, 26) . In the present study, the three type IV GBS strains used were poorly pathogenic in terms of acute lethality for mice. LD50s after i. (27, 34) (6, 12) . LD50s lower than those obtained with the type IV GBS strains have been reported for type I (3, 34) and II (9, 14) GBS. Overall, these results seem to indicate that type IV GBS strains are less virulent for mice with respect to other GBS serotypes.
As seen in experimental GBS infections (23), the high LD50s of type IV GBS in murine models are possibly correlated with the relatively low sialic acid content of type IV polysaccharide as well as to the thinness of capsular material present on the bacterial surface (23 (7, 32) . Polyarthritis was also produced in mice by i.v. injection of the cell wall or peptidoglycan fraction of group A streptococci (20) . In our experimental model, septic arthritis was induced only by live type IV GBS and not with inactivated cells or cell sonic extracts containing group-and typespecific polysaccharides.
During infection, microorganisms were always isolated from the affected joints and the sera of arthritic mice contained type-and group-specific antigens for about 3 weeks after infection. A large number of viable type IV GBS were necessary to establish a chronic infection in mice and overcome host resistance. The early clinical manifestations of arthritis, the presence of purulent exudate, the longlasting infection of type IV GBS from the affected joints, and the failure to produce arthritis with inactivated or sonicated cells all suggest a tropism of live type IV GBS for articular tissue. However, the exact mechanisms by which live GBS cells promote the disease remain to be clarified. The determination of antibody and leukocyte responses during the course of infection showed that both type IV-specific IgM and IgG were produced but were unable to eradicate infection in the organs of animals until a marked leukocytosis, mainly involving polymorphonuclear leukocytes and monocytes, was reached on day 15. A crucial role of phagocytic cells, with or without opsonizing antibodies, has been claimed for GBS types la and III (3-5, 10, 33) . Our observations that type IV GBS infection cannot be eliminated by the host during the first days after challenge when antibodies are not present and phagocytic cells have not yet reached their maximum number have been confirmed by experiments which demonstrated that hyperimmune rabbit antisera, administered 6 h before GBS infection, greatly reduced the incidence of arthritis; in fact, only 15% of hyperimmune serum-treated mice had arthritis versus 65% of untreated mice. Furthermore, hyperimmune anti-GBS sera decreased the number of GBS in the various organs (data not shown).
In conclusion, systemic infection of CD-1 mice with appropriate numbers of different strains of type IV GBS resulted in a chronic infection with an early development and high incidence of septic arthritis. This may represent an interesting finding considering that no experimental model is available for studies on experimental pathogenicity, chemotherapy, and immune mechanisms of host resistance to type IV GBS infection.
